Biotechnology Healthcare - September/October 2008 - (Page 4)

Biotechnology Healthcare FEATURE ARTICLES COVER STORY MOLECULAR DIAGNOSTICS M CARE MANAGEMENT COST-EFFECTIVENESS COST MANAGEMENT THE IMPACT OF BIOLOGICS ON HEALTH, BUSINESS, AND BENEFITS SEPTEMBER/OCTOBER 2008 The Official Journal of the Biologic Finance and Access Council www.biotechnologyhealthcare.com Healthcare Reform’s Effects on Biologic Access 18 Nobody is out on the hustings talking about cost-sharing or fair means of access to biologics. But a pipeline loaded with them may ultimately force the government to address fundamental cost issues in healthcare. How the candidates’ positions play into this. Breast Cancer Status Testing: A Crapshoot With Deadly Odds 23 Incorrect test results defining HER2 status are not uncommon. Getting it wrong leads to spending a fortune on treatment that won’t work or denying therapy to people whose lives could be spared by it. So High-Tech, Yet So Simple 35 Nonadherence is an incredibly complex and difficult-to-address problem. Several products designed to appeal to tech-savvy patients offer the promise of one simple solution. M The Evolution of Ascertaining the Value Proposition 39 Overseas, government payers challenge biopharma companies to show evidence of costeffectivess. Collaboration there could provide a model for U.S. payers and manufacturers. FOCUS: MULTIPLE SCLEROSIS AT A GLANCE: Multiple Sclerosis 6 Prevalence of disease, economics of care, and implications for payers, as told in charts. Trends, Issues, and Perspectives In the Management of MS 29 The nature of multiple sclerosis and its treatment differ from some other conditions that are treated with biologics, leading to opportunities that could help to close gaps in patient care. DEPARTMENTS Openers 2 What really matters, anyway? Editorial/David B. Nash, MD, MBA 3 A profile of the pharma industry. DrugTrack 8 Approvals, research, conference coverage. Personalized Medicine 11 Pluses, minuses of online genetic testing. Specialty Pharmacy 43 The value of value-added services. Employer to Employer 45 An academic setting has its advantages. Health Plan Confidential 47 Time to take a harder look at the QALY? Trends 49 Biologic sales growth double the rest. BIOTECHNOLOGY HEALTHCARE (ISSN 1554-169x) is published bimonthly by BioCommunications LLC, 780 Township Line Road, Yardley, PA 19067. This is Volume 5, Number 3. Standard postage paid at Morrisville, Pa., and at additional mailing offices. Price: $18 per copy, $95 per year in the United States; $120 per year elsewhere. Phone: (267) 685-2788; fax (267) 6852966; paid subscription inquiries (267) 685-2789. Letters to the editor will be considered for publication and should be sent to the address above. Copyright 2008, BioCommunications LLC. INDEXED BY CINAHL AND INTERNATIONAL PHARMACEUTICAL ABSTRACTS COVER: TOM WHITE M http://www.biotechnologyhealthcare.com

Table of Contents Feed for the Digital Edition of Biotechnology Healthcare - September/October 2008

Biotechnology Healthcare - September/October 2008 Openers Editorial/David B. Nash, MD, MBA Contents At a Glance: Multiple Sclerosis Drug Track Personalized Medicine Healthcare Reform’s Effects on Biologic Access Breast Cancer Status Testing: A Crapshoot With Deadly Odds Trends, Issues, and Perspectives In the Management of MS So High-Tech, Yet So Simple The Evolution of Ascertaining the Value Proposition Specialty Pharmacy Employer to Employer Health Plan Confidential Trends

Biotechnology Healthcare - September/October 2008

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.